We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+70.52%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$500M
AUM Growth
+$238M
Cap. Flow
+$166M
Cap. Flow %
33.16%
Top 10 Hldgs %
50.21%
Holding
73
New
32
Increased
7
Reduced
5
Closed
27

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$55.5M
2
RNAM
Avidity Biosciences
RNAM
+$26.7M
3
RPTX
Repare Therapeutics
RPTX
+$21.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$20.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$14.1M
4
MRNA icon
Moderna
MRNA
+$13.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMTX
1
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$59.5M 11.89%
+1,280,000
New +$55.5M
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$31.2M 6.24%
200,000
+117,708
+143% +$17.9M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.83B
$26M 5.2%
+2,000,000
New +$8.86M
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$25.6M 5.11%
+926,454
New +$26.7M
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$20.3M 4.05%
+666,894
New +$21.4M
BNTX icon
6
BioNTech
BNTX
$23.2B
$19.7M 3.93%
+295,000
New +$14.7M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
$18.9M 3.77%
800,000
+606,871
+314% +$11.4M
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
$16.9M 3.38%
+268,500
New +$14.8M
AMTI
9
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$16.7M 3.34%
+664,186
New +$16.8M
TGTX icon
10
TG Therapeutics
TGTX
$8.65B
$16.6M 3.31%
850,000
+600,156
+240% +$9.67M
AKBA icon
11
Akebia Therapeutics
AKBA
$338M
$16.3M 3.26%
+1,200,000
New +$12.4M
BTAI icon
12
BioXcel Therapeutics
BTAI
$26.4M
$15.9M 3.18%
+18,750
New +$12.2M
IMVT icon
13
Immunovant
IMVT
$8.27B
$15.2M 3.04%
+625,000
New +$13.4M
KROS icon
14
Keros Therapeutics
KROS
$207M
$15M 3%
+400,000
New +$12.3M
PLRX icon
15
Pliant Therapeutics
PLRX
$68.1M
$14.6M 2.91%
+456,426
New +$12.1M
PCVX icon
16
Vaxcyte
PCVX
$8.05B
$14.4M 2.87%
+455,000
New +$14.6M
BMY.RT
17
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$14.3M 2.86%
4,000,000
+2,724,500
+214% +$9.83M
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
$10.8M 2.16%
400,000
+247,856
+163% +$6.84M
AKUS
19
DELISTED
Akouos Inc
AKUS
$10.1M 2.02%
+450,000
New +$10M
PRNB
20
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$8.97M 1.79%
+150,000
New +$9.27M
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.52M 1.7%
135,000
-50,933
-27% -$3.49M
PASG icon
22
Passage Bio
PASG
$15.6M
$8.47M 1.69%
17,222
-12,945
-43% -$5.82M
FULC icon
23
Fulcrum Therapeutics
FULC
$251M
$7.5M 1.5%
410,000
-122,520
-23% -$1.93M
CALT
24
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$6.99M 1.4%
+300,000
New +$5.94M
OBSV
25
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.86M 1.37%
+1,165,000
New +$4.4M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2020 Portfolio in Review

As of Q2 2020, Logos Global Management held 73 positions worth $500M, up 90% from $263M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $166M of net new capital in Q2 2020, opening 32 new positions and adding to 7 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Passage Bio, an estimated $5.82M trimmed.

  • Logos Global Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.
  • Logos Global Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020, an estimated $17.9M increase.
  • Logos Global Management's biggest Q2 2020 reduction was Passage Bio, cutting an estimated $5.82M.
  • Logos Global Management fully exited AbbVie in Q2 2020, selling an estimated $20.2M.
  • Logos Global Management's ten largest holdings make up 50% of its $500M portfolio in Q2 2020.
  • Logos Global Management opened 32 new positions and closed 27 in Q2 2020.
  • Logos Global Management's portfolio value rose 90% quarter-over-quarter to $500M.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.